Jul.30 -- Eli Lilly Chief Financial Officer Joshua Smiley says the drugmaker expects to start registratrion trials of its coronavirus antibody treatment "within the next few weeks" and to produce 100,000 doses of a successful therapeutic by the end of 2020. He speaks on "Bloomberg Markets: European Close."